AJM300, a novel oral antagonist of α4‐integrin, sustains an increase in circulating lymphocytes: A randomised controlled trial in healthy male subjects

• Published in: British journal of clinical pharmacology Vol. 86; no. 3; pp. 591 - 600
• Main Authors: Fukase, Hiroyuki, Kajioka, Toshifumi, Oikawa, Ichiro, Ikeda, Naoki, Furuie, Hidetoshi
• Format: Journal Article
• Language: English
• Published: England John Wiley and Sons Inc 01.03.2020
• Subjects: clinical trial; Original; pharmacodynamics; pharmacokinetics; Phase I; randomised controlled trial; clinical trial; pharmacokinetics; randomised controlled trial; Phase I; pharmacodynamics

Aims AJM300 is an oral antagonist of α4‐integrin that reduces inflammation by blocking leucocyte trafficking. This study aimed to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of AJM300 in healthy male subjects. Methods A total of 23 subjects were randomised to receive 240...